Please ensure Javascript is enabled for purposes of website accessibility

Why Atossa Therapeutics Stock Is Tumbling Today

By Keith Speights - Jun 9, 2021 at 11:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The sell-off resulted from the company's announcement of phase 2 data for experimental breast cancer drug endoxifen.

What happened

Shares of Atossa Therapeutics (ATOS 5.00%) were tumbling 22.8% as of 11:36 a.m. EDT on Wednesday. The decline came after the company announced final results from its phase 2 clinical study evaluating oral endoxifen in treating breast cancer with administration between diagnosis and surgery.

So what

Today's sell-off of the biotech stock appears to be a case of investors sticking with the old adage to "buy the rumor and sell the news." Atossa's shares skyrocketed 539% year to date as of the market close on Tuesday.

The company's news was pretty good, although some investors could have been hoping for even better results. Atossa reported that oral endoxifen met the primary endpoint of the phase 2 study. The experimental drug reduced Ki-67, a measure of tumor cell activity, by 65.1% on average. Even better, all patients in the study receiving endoxifen experienced a reduction in Ki-67 to below 25%, an indication that the drug could improve long-term survival.

Healthcare professional holding a pink ribbon for breast cancer awareness.

Image source: Getty Images.

Atossa also said that endoxifen was "considered safe and well tolerated" in the phase 2 study. All of the adverse events observed in the study were mild. No adverse events led to patients discontinuing participation in the study.

Now what

What's next for Atossa? CEO Steven Quay said the company has begun a formal nonclinical toxicology program required to seek U.S. approval of oral endoxifen. He added that Atossa plans to file for approval to advance the drug into the next round of clinical testing as soon as possible.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Atossa Genetics Inc. Stock Quote
Atossa Genetics Inc.
ATOS
$1.05 (5.00%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.